Company Overview: Catalyst Biosciences

Industry News

14 Dec

Catalyst Biosciences Announces Appointment of Edward Williams to its Board of Directors

Former Novo Nordisk Executive Strengthens Catalyst’s Hemophilia Expertise SOUTH SAN FRANCISCO, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the appointment of Edward Williams to the board of directors, effective Jan....

Read more

11 Dec

Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference

Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to...

Read more

1 Nov

Catalyst Biosciences Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d/ISU304 in Hemophilia B Patients at American Society for Hematology

CB 2679d demonstrated a 22-fold greater potency over BeneFIX and a longer mean residence time SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced an oral presentation, entitled “Phase...

Read more

26 Oct

Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors

Senior pharmaceutical executive with extensive experience in hematology and hemophilia Led Baxalta’s Global Blood Disorders Franchise within the Hematology Division SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced...

Read more

24 Oct

Catalyst Biosciences and Mosaic Biosciences Enter into Strategic Collaboration to Develop Intravitreal Anti-Complement Factor 3 (C3) Products for the Treatment of Dry AMD and Other Retinal Diseases

Collaboration aims to develop best-in-class anti-C3 intravitreal products with quarterly dosing frequency and better potency C3 is a clinically validated target in dry age-related macular degeneration, a large multi-billion-dollar market with no approved therapies SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., Oct. 24, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences,...

Read more

26 Sep

Catalyst Biosciences Granted FDA Orphan Drug Designation for Subcutaneous Recombinant Human Factor IX Variant for Treatment of Hemophilia B

— Orphan drug designation provides marketing exclusivity if approved by FDA — SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for CB 2679d/ISU304, Catalyst’s highly potent subcutaneous next-generation recombinant human Factor...

Read more

Page 1 of 41234

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address